A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Comparison of: (2S,4R)-4-[F-18]Fluoroglutamine, [C-11]Methionine, and 2-Deoxy-2-[F-18]Fluoro-D-Glucose and Two Small-Animal PET/CT Systems Imaging Rat Gliomas




Julkaisun tekijät: Miner Maxwell WG, Liljenbäck Heidi, Virta Jenni, Helin Semi, Eskola Olli, Elo Petri, Teuho Jarmo, Seppälä Kerttu, Oikonen Vesa, Yang Guangli, Kindler-Röhrborn Andrea, Minn Heikki, Li Xiang-Guo, Roivainen Anne

Kustantaja: FRONTIERS MEDIA SA

Julkaisuvuosi: 2021

Journal: Frontiers in Oncology

Tietokannassa oleva lehden nimi: FRONTIERS IN ONCOLOGY

Lehden akronyymi: FRONT ONCOL

Volyymi: 11

Sivujen määrä: 10

ISSN: 2234-943X

DOI: http://dx.doi.org/10.3389/fonc.2021.730358


Tiivistelmä

Purpose: The three positron emission tomography (PET) imaging compounds: (2S,4R)-4-[F-18]Fluoroglutamine ([F-18]FGln), L-[methyl-C-11]Methionine ([C-11]Met), and 2-deoxy-2-[F-18]fluoro-D-glucose ([F-18]FDG) were investigated to contrast their ability to image orthotopic BT4C gliomas in BDIX rats. Two separate small animal imaging systems were compared for their tumor detection potential. Dynamic acquisition of [F-18]FGln was evaluated with multiple pharmacokinetic models for future quantitative comparison.

Procedures: Up to four imaging studies were performed on each orthotopically grafted BT4C glioma-bearing BDIX rat subject (n = 16) on four consecutive days. First, a DOTAREM(R) contrast enhanced MRI followed by attenuation correction CT and dynamic PET imaging with each radiopharmaceutical (20 min [C-11]Met, 60 min [F-18]FDG, and 60 min [F-18]FGln with either the Molecubes PET/CT (n = 5) or Inveon PET/CT cameras (n = 11). Ex vivo brain autoradiography was completed for each radiopharmaceutical and [F-18]FGln pharmacokinetics were studied by injecting 40 MBq into healthy BDIX rats (n = 10) and collecting blood samples between 5 and 60 min. Erythrocyte uptake, plasma protein binding and plasma parent-fraction were combined to estimate the total blood bioavailability of [F-18]FGln over time. The corrected PET-image blood data was then applied to multiple pharmacokinetic models.

Results: Average BT4C tumor-to-healthy brain tissue uptake ratios (TBR) for PET images reached maxima of: [F-18]FGln TBR: 1.99 +/- 0.19 (n = 13), [F-18]FDG TBR: 1.41 +/- 0.11 (n = 6), and [C-11]Met TBR: 1.08 +/- 0.08, (n = 12) for the dynamic PET images. Pharmacokinetic modeling in dynamic [F-18]FGln studies suggested both reversible and irreversible uptake play a similar role. Imaging with Inveon and Molecubes yielded similar end-result ratios with insignificant differences (p > 0.25).

Conclusions: In orthotopic BT4C gliomas, [F-18]FGln may offer improved imaging versus [C-11]Met and [F-18]FDG. No significant difference in normalized end-result data was found between the Inveon and Molecubes camera systems. Kinetic modelling of [F-18]FGln uptake suggests that both reversible and irreversible uptake play an important role in BDIX rat pharmacokinetics.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2021-29-11 at 12:04